Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354155 · ClinicalTrials.gov registry record · Phase 2
COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial
A Phase 2 study, sponsored by Johns Hopkins All Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT04354155 is a Phase 2 study that has completed, run by Johns Hopkins All Children's Hospital. The registered enrollment target is 40 participants.
The verdict
NCT04354155, a Phase 2 study, has completed, sponsored by Johns Hopkins All Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, dose-requirements, and exploratory efficacy of twice-daily subcutaneous enoxaparin as venous thromboembolism prophylaxis in children (birth to 18 years) hospitalized with signs and/or symptoms of SARS-CoV-2 infection (i.e., COVID-19).
Interventions
- DRUG Enoxaparin Prefilled Syringe [Lovenox]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2021-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04354155
The ClinicalTrials.gov registry entry for NCT04354155 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins All Children's Hospital, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enoxaparin Prefilled Syringe [Lovenox] is the first listed.
NCT04354155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04354155 about?
NCT04354155 is a clinical study titled "COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial". The purpose of this study is to evaluate the safety, dose-requirements, and exploratory efficacy of twice-daily subcutaneous enoxaparin as venous thromboembolism prophylaxis in children (birth to 18 years) hospitalized with signs and/or symptoms of SARS-CoV-2 infection (i.e., COVID-19).
What is the current status of trial NCT04354155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-06-02. Estimated completion is 2021-06-04.
What interventions are being tested in trial NCT04354155?
The interventions under investigation include: Enoxaparin Prefilled Syringe [Lovenox] (DRUG).
Who is sponsoring clinical trial NCT04354155?
This trial is sponsored by Johns Hopkins All Children's Hospital, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.